



Global News and Expert Analysis on Pharma Policy and Regulation

Successfully Navigate Pharma Regulations and Policy

Today's pharma regulatory environment is complex, with new approaches in an array of areas including clinical trial design, expedited review pathways, digital tools, and innovative reimbursement programs. Many of these policies offer new opportunities for pharma companies, but staying on top of critical developments – and understanding them – is an enormous task.

Since 1939, *Pink Sheet* has been the leader in providing trusted insights on the news plus trend analysis to help you navigate pharma policy – enabling you to understand what is happening today and anticipate what will happen tomorrow.

Pink Sheet equips you with strategic information to bring products to market more quickly and successfully, obtain reimbursement coverage and avoid compliance missteps in areas like manufacturing and marketing that could take products off the market.



GLOBAL CONTENT FROM TRUSTED EXPERTS

60+ journalists provide first-hand coverage of key events from locations around the globe. Sources and readers alike trust our coverage as independent, thorough and objective, thanks to our 80-year track record of excellence.



CROSSING INDUSTRY SILOS

Coverage including innovator prescription products, biosimilars and generic drugs, as well as coverage across different regulatory agencies allows us to identify cross-cutting implications of policy. We connect up regulatory developments and business impact.



INSIGHT BEYOND THE HEADLINES

Pink Sheet does much more than keep you up to date. Our staff expertise and access to decision-makers and industry leaders enable us to deliver coverage with analysis of next steps, implications and trends; and actionable insights on what developments could mean for your business.



POWERFUL DIGITAL PLATFORM

New user-friendly, digital platform is responsive on any mobile device, includes a robust boolean search and the ability to create custom, fully responsive email alerts.

Must-know information

- Opportunities from new approval pathways and drug development incentive programs.
- Emerging regulatory topics, such as biomarkers and digital tools.
- New payer requirements at both government agencies and private insurers.
- Regulatory agency organization and staffing, and their impact on the drug review process.
- **Legislation** affecting agency policies and budgets.
- **Post-approval issues**, including marketing restrictions and safety surveillance.
- Patent issues and litigation trends.
- Drug approvals requirements at agencies including US FDA, European Medicines Agency and China National Medical Products Administration, plus strategic takeaways from precedent-setting approvals.

Exclusive features


- US FDA and EU Performance Trackers,

 a data resource tracing products from submission to approval and tracking areas of particular regulatory interest, such as drugs designated as Breakthrough or PRIME products.
- **Drug Review Profiles**, an in-depth look behind approval decisions with key insights and lessons learned.
- Global Guidance Tracker, a monthly update of new rules and guidances with links to official documents.
- Special focus areas: manufacturing, reimbursement, market access, and regional coverage.

PLUS

ASK THE ANALYST: Ask our expert journalists about any of our news stories, data and analysis when you need additional information.

Leading industry insight on a leading industry platform





Video, audio, and proprietary data sets bring our articles and analyses to life.



Numerous search filters allow for precise content targeting, and articles and searches can be saved and shared with one click.



Set custom email alerts on any topic or search criteria so you never miss what you need to know most.



To learn more about the advantages we can deliver to your company, please visit: pink.citeline.com